Back to top
more

TG Therapeutics (TGTX)

(Delayed Data from NSDQ)

$21.39 USD

21.39
4,059,646

+0.89 (4.34%)

Updated Jul 11, 2024 04:00 PM ET

Pre-Market: $21.43 +0.04 (0.19%) 8:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (170 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TGTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

TG Therapeutics, Inc. [TGTX]

Reports for Purchase

Showing records 161 - 180 ( 277 total )

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 161

11/09/2015

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 162

11/09/2015

Company Report

Pages: 7

3Q15 Results; Looking for Momentum into ASH; Reiterate Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 163

11/02/2015

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 164

11/02/2015

Company Report

Pages: 7

Upcoming Clinical Milestones and 3Q15 Results Previews

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 165

09/18/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 166

09/17/2015

Daily Note

Pages: 4

SPA for "1303" Study; Approval Potential for Two Drugs and Two Settings

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 167

08/25/2015

Industry Report

Pages: 6

Biotech Names for the Turn and the Long Haul

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 168

08/12/2015

Company Report

Pages: 8

Resuming Coverage with Buy Rating and $22 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 169

08/10/2015

Company Report

Pages: 6

2Q15 Results; GENUINE and Expanding Programs; Reiterate Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 170

08/10/2015

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 171

06/19/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 172

06/18/2015

Company Report

Pages: 6

We Believe Data Continue to Act as Strong GENUINE Proxy; Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 173

06/05/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 174

06/05/2015

Company Report

Pages: 11

The Opportunity for 1101,1202 in CLL: Efficacy - Safety Differentiation

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 175

06/03/2015

Industry Report

Pages: 8

ASCO Highlights Part 2-Our Thoughts from McCormick Place

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 176

06/02/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 177

06/01/2015

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 178

06/01/2015

Company Report

Pages: 8

An Enticing Threesome; Reiterate Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 179

06/01/2015

Industry Report

Pages: 15

ASCO Highlights Part 1-Our Thoughts from McCormick Place

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 50.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 180

05/31/2015

Company Report

Pages: 13

No ASCO Surprises; Differentiation Continues; Reiterate Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party